(-)-Sparteine | CAS#90-39-1 | anticonvulsant

(-)-Sparteine
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561625

CAS#: 90-39-1

Description: (-)-Sparteine is a natural anticonvulsant. It inhibits seizures, delays the onset of convulsive behavior, and activates the M2 and M4 subtypes of mAChRs.

Chemical Structure

(-)-Sparteine

CAS# 90-39-1

Instruction

Theoretical Analysis

MedKoo Cat#: 561625
Name: (-)-Sparteine
CAS#: 90-39-1
Chemical Formula: C15H26N2
Exact Mass: 234.21
Molecular Weight: 234.380
Elemental Analysis: C, 76.87; H, 11.18; N, 11.95

Price and Availability

Size	Price	Availability
500mg	USD 750	2 Weeks
1g	USD 1250	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: (-)-Sparteine; Sparteine;

IUPAC/Chemical Name: (7S,7aS,14S)-dodecahydro-2H,6H-7,14-methanodipyrido[1,2-a:1',2'-e][1,5]diazocine

InChi Key: SLRCCWJSBJZJBV-LOKSQKBWSA-N

InChi Code: InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15?/m0/s1

SMILES Code: [C@@H]1(C2)C3CCCCN3C[C@H]2[C@@H]4CCCCN4C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 234.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Villalpando-Vargas F, Medina-Ceja L. Sparteine as an anticonvulsant drug: Evidence and possible mechanism of action. Seizure. 2016 Jul;39:49-55. doi: 10.1016/j.seizure.2016.05.010. Epub 2016 May 24. Review. PubMed PMID: 27262285.

2: Kolodiazhnyi OI. Recent advances in asymmetric synthesis of Р-stereogenic phosphorus compounds. Top Curr Chem. 2015;360:161-236. doi: 10.1007/128_2014_564. Review. PubMed PMID: 25326833.

3: Basova NE, Kormilitsyn BN, Rozengart EV, Saakov VS, Suvorov AA. [Derivatives of lupinin and epilupinin as ligands of various cholinesterases]. Zh Evol Biokhim Fiziol. 2012 Jan-Feb;48(1):8-16. Review. Russian. PubMed PMID: 22567970.

4: Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol. 2007 Apr;63(4):321-33. Epub 2007 Feb 2. Review. PubMed PMID: 17273835.

5: Daly JW. Nicotinic agonists, antagonists, and modulators from natural sources. Cell Mol Neurobiol. 2005 Jun;25(3-4):513-52. Review. PubMed PMID: 16075378.

6: Szewczuk-Bogusławska M, Grzesiak M, Beszłej JA, Kiejna A. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy]. Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104. Review. Polish. PubMed PMID: 15779673.

7: Lötsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43(14):983-1013. Review. PubMed PMID: 15530129.

8: Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95. Review. PubMed PMID: 15499174.

9: Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev. 2004 May;36(2):243-77. Review. PubMed PMID: 15237854.

10: Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur J Clin Invest. 2003 Nov;33 Suppl 2:17-22. Review. PubMed PMID: 14641552.

11: Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37. Epub 2003 Nov 15. Review. PubMed PMID: 14618296.

12: Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102. Review. PubMed PMID: 12551730.

13: Mehvar R, Brocks DR, Vakily M. Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs. Clin Pharmacokinet. 2002;41(8):533-58. Review. PubMed PMID: 12102640.

14: Michael JP. Indolizidine and quinolizidine alkaloids. Nat Prod Rep. 2001 Oct;18(5):520-42. Review. PubMed PMID: 11699884.

15: Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83. Review. PubMed PMID: 11532381.

16: Ohmiya S, Saito K, Murakoshi I. [Recent progress on the lupine alkaloids in leguminous plants growing mainly in Japan]. Yakugaku Zasshi. 2000 Oct;120(10):923-34. Review. Japanese. PubMed PMID: 11082704.

17: Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000 Apr;10(3):187-216. Review. PubMed PMID: 10803676.

18: Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. Review. PubMed PMID: 10774624.

19: Weber WW. Populations and genetic polymorphisms. Mol Diagn. 1999 Dec;4(4):299-307. Review. PubMed PMID: 10671640.

20: Sano S. [Development of highly stereoselective reactions utilizing heteroatoms--asymmetric synthesis of alpha-substituted serines]. Yakugaku Zasshi. 2000 Jan;120(1):28-41. Review. Japanese. PubMed PMID: 10655780.

Your view history

(-)-Sparteine featured